Replies to post #70854 on Biotech Values

[apljack]

Ereska/JAV

Genisi and anyone else who might be interested:

I suspect that Ereska for analgesia will be a big hit for breakthrough pain mostly because of the subjective experience reported by so many street users of ketamine. The type of dissociative euphoria that ketamine can provide will be a big relief for the target populations of pain patients who have a miserable life because of the pain they are experiencing. These same patients will have been on opioids, have developed a tolerance to the opioids, and most will tell their doctors (and anyone else who will listen) that the opioids dull the pain, but don't eliminate it. When one lives with this kind of pain, the ability to enter into a controlled dissociative state will be a great relief, even for a short amount of time.

(Biowatch, thanks for the PM's; I could fill your ears with the struggle to get DoD to fund brain injury rehab outside of the VA system)

aj